source
- FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival dataThe FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…
- Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billionJohnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…